Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Bone Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


7 drugs have received FDA approval for Bone Cancer . 223, Denosumab, Doxorubicin Hydrochloride, Filgrastim, Pamidronate Disodium, Ruxolitinib Phosphate and Zoledronic Acid
52 drugs have a clinical trial registered for Bone Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 155 clinical trials for Bone Cancer,
78 of which have one or more drug interventions,
77 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 1435 Cell Line Models for Bone Cancer.

Source: COSMIC
(see details)

Chemistry


There are 1054 Compounds which have been tested in Bone Cancer , 850 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Bone Cancer:
Bone Marrow Neoplasms
Bone Neoplasms
Giant Cell Tumor of Bone

The following terms have been mapped from cancer.gov to Bone Cancer:
Broken bones and other bone problems caused by multiple myeloma or by solid tumors that have metastasized (spread) to bone. This use is approved for the Xgeva brand of denosumab
Breast cancer that has metastasized (spread) to bone
Giant cell tumor of the bone. It is used in adults and in adolescents whose bones have finished growing
Multiple myeloma and cancers that have spread to the bone
Multiple myeloma that has metastasized to bone
Myeloablative chemotherapy before a bone marrow transplant
Myelofibrosis (a bone marrow disease) that is intermediate or high-risk, including the following types:Primary myelofibrosis
Osteoporosis in men and postmenopausal women who have a high risk of breaking bones. This use is approved for the Prolia brand of denosumab
Prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels). It is used in patients whose disease has metastasized (spread) to the bones and is causing symptoms but has not spread to other organs
Soft tissue and bone sarcomas